中国胃癌外科发展的机遇与挑战

黄埔,  季科,  步召德,  季加孚

downloadPDF
文章导航 > 中国肿瘤临床  > 2019 >  46(1): 2-5
黄埔, 季科, 步召德, 季加孚. 中国胃癌外科发展的机遇与挑战[J]. 中国肿瘤临床, 2019, 46(1): 2-5. doi: 10.3969/j.issn.1000-8179.2019.01.154
引用本文: 黄埔, 季科, 步召德, 季加孚. 中国胃癌外科发展的机遇与挑战[J]. 中国肿瘤临床, 2019, 46(1): 2-5. doi: 10.3969/j.issn.1000-8179.2019.01.154
shu
Huang Pu, Ji Ke, Bu Zhaode, Ji Jiafu. Development of Chinese gastric cancer surgery: opportunities and challenges[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(1): 2-5. doi: 10.3969/j.issn.1000-8179.2019.01.154
Citation: Huang Pu, Ji Ke, Bu Zhaode, Ji Jiafu. Development of Chinese gastric cancer surgery: opportunities and challenges[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(1): 2-5. doi: 10.3969/j.issn.1000-8179.2019.01.154
shu

中国胃癌外科发展的机遇与挑战

doi: 10.3969/j.issn.1000-8179.2019.01.154

  • 北京大学肿瘤医院暨北京肿瘤防治研究所胃肠中心（北京市100142）

详细信息
    作者简介:

    黄埔  专业方向为胃肠肿瘤临床及基础治疗等。E-mail：ahaqhhpdr@163.com

    季加孚 教授，现任北京大学肿瘤医院院长，北京市肿瘤防治研究所所长，北京大学肿瘤研究中心主任，教育部恶性肿瘤发病机制及转化重点实验室主任，享受国务院特殊津贴。兼任国际胃癌学会（IGCA）主席，中国抗癌协会副理事长，中国医疗保健国际交流促进会副会长，中华医学会常务理事，外科学分会常委兼秘书长，美国外科学院会士（FACS），英国皇家外科学院院士（FRCS），英国皇家生物学会会士（FRSB），亚洲外科学会（ASA）常委。致力于胃癌外科临床与科研，率先建立并统一中国胃癌标准手术规范，创建中国胃肠肿瘤外科联盟，在国内率先创建进展期胃癌综合治疗新模式，显著提高了中国进展期胃癌患者的生存率。创建世界规模最大的胃癌及癌前病变临床样本资源库及共享平台，有效解决中国胃癌重大研究项目样本资源短缺的难题。曾获中华医学科技奖一等奖，教育部科技进步一等奖，中国抗癌协会科技奖一等奖，吴阶平—保罗·杨森医学药学奖，国家卫生计生委突出贡献中青年专家等多项荣誉。以第一作者或通信作者在The Lancet、Cell Research等SCI期刊发表论文100余篇，总影响因子3401

    通讯作者:

    季加孚  jijiafu@hsc.pku.edu.cn

Development of Chinese gastric cancer surgery: opportunities and challenges

  • Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China

More Information

    摘要
  • 摘要: 伴随着人工智能与大数据时代的来临，基因组学的发展以及影像技术的更新，中国胃癌外科在腔镜外科技术、加速康复外科、多学科综合治疗协作、精准医疗等多方面均面临着前所未有的机遇与挑战。腔镜外科手术有着切口小、恢复快等优势，进一步降低手术并发症发生率是新时代医患的共同需求。微创肿瘤外科治疗面临创新，需要新的平台及新的思维。人工智能与大数据的发展，对临床医生的常规诊断和治疗提出新挑战。顺应科技的发展，因地制宜，鼓励多中心合作研究，完善专科数据的标准化与互联互通，完成从经验医学向循证医学的转变，促进胃癌治疗的标准化、规范化和个体化，为患者提供精准化的诊疗，是当前胃癌外科发展的机遇与挑战。

     

    Abstract: With the approaches of artificial intelligence and big data, the development of cancer genomics and updating of imaging technology, gastric cancer surgery is facing great challenges and opportunities. The main focus is on laparoscopic surgery technology, enhanced recovery after surgery, multidisciplinary comprehensive treatment, and precision medicine. Considering the common demand for reduced complication rate among doctors and patients, laparoscopic surgery has become widely popular owing to its advantages of small incision and rapid recovery. Furthermore, the development of artificial intelligence and big data has raised a new challenge in routine diagnosis and treatment. As a result, we encourage multicenter cooperation, and data standardization and sharing. At present, completion of the transition from empirical medicine to evidence-based medicine and promotion of the individualization and standardization of gastric cancer treatment are needed.

     

    • HTML全文
    • 参考文献(30)
  • [1] Zhang SW, Yang ZX, Zheng RS, et al. Incidence and mortality of stomach cancer in China, 2014[J]. Chin J Cancer Res, 2018, 30(3):291-298. doi: 10.21147/j.issn.1000-9604.2018.03.01
    [2] Strong VE, Wu AW, Selby LV, et al. Differences in gastric cancer survival between the U.S. and China[J]. J Surg Oncol, 2015, 112(1):31-37. doi: 10.1002/jso.23940
    [3] Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation[J]. Br J Anaesth, 1997, 78(5):606-617. doi: 10.1093/bja/78.5.606
    [4] 中国研究型医院学会机器人与腹腔镜外科专业委员会.胃癌胃切除手术加速康复外科专家共识(2016版)[J].中华消化外科杂志, 2017, (16):17. http://d.old.wanfangdata.com.cn/Periodical/xhwk201701003
    [5] 陈凛, 陈亚进, 董海龙, 等.加速康复外科中国专家共识及路径管理指南(2018版)[J].中国实用外科杂志, 2018, 38(1):1-20. http://d.old.wanfangdata.com.cn/Periodical/xhyx201806002
    [6] Hiki N, Katai H, Mizusawa J, et al. Long-term outcomes of laparoscopyassisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage Ⅰ gastric cancer: a multicenter phase Ⅱ trial (JCOG0703) [J]. Gastric Cancer, 2017, 21(1):1-7.
    [7] Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: A randomized controlled trial[J]. J Clin Oncol, 2016, 34(12):1350-1357. doi: 10.1200/JCO.2015.63.7215
    [8] Shinohara T, Satoh S, Kanaya S, et al. Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: A retrospective cohort study [J]. Surgical Endoscopy, 2013, 27(1):286-294. doi: 10.1007/s00464-012-2442-x
    [9] Kim HI, Han SU, Yang HK, et al. Multicenter prospective comparative study of robotic versus laparoscopic gastrectomy for gastric adenocarcinoma[J]. Annals of Surgery, 2016, 263(1):103-109. doi: 10.1097/SLA.0000000000001249
    [10] Sano T. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan Clinical Oncology Group Study JCOG 0110-MF[J]. Jpn J Clini Oncol, 2002, 32(9):363-364. doi: 10.1093/jjco/hyf085
    [11] 季加孚, 范彪, 步召德.精准医学在胃肠肿瘤外科中的内涵与临床实践[J].中华普外科手术学杂志(电子版), 2016, 10(3):185-188. doi: 10.3877/cma.j.issn.1674-3946.2016.03.002
    [12] Sasako M, Mcculloch P, Kinoshita T, et al. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer[J]. Br J Surg, 2010, 82(3):346-351. http://cat.inist.fr/?aModele=afficheN&cpsidt=3483018
    [13] Lee J, Lim DH, Kim S, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol, 2012, 30(3): 268-273. doi: 10.1200/JCO.2011.39.1953
    [14] Strong VE, Yoon SS. Extended lymphadenectomy in gastric cancer is debatable[J]. World J Surg, 2013, 37(8):1773-1777. doi: 10.1007/s00268-013-2070-1
    [15] Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer[J]. Br J Surg, 2014, 101(2):23-31. doi: 10.1002/bjs.9345
    [16] Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 openlabel, randomised controlled trial[J]. Lancet, 2012, 379(9813):315-321. doi: 10.1016/S0140-6736(11)61873-4
    [17] Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011, 29(13):1715-1721. doi: 10.1200/JCO.2010.33.0597
    [18] Al-Batran SE, Pauligk C, Homann N, et al. LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)[J]. Ann Oncol, 2017, 28(suppl_3). http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_MED201712280549
    [19] Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21 Suppl 5(5):v50-v54. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_2998825
    [20] Fuchs CS, DoiT, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phaseⅡ clinical KEYNOTE-059 trial [J]. Jama Oncol, 2018, 4(5):e180013. doi: 10.1001/jamaoncol.2018.0013
    [21] Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro- oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538- 12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111):2461. doi: 10.1016/S0140-6736(17)31827-5
    [22] Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial[J]. Jama Oncology, 2017, 3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762
    [23] Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine[J]. Nature, 2015, 526(7573):336-342. doi: 10.1038/nature15816
    [24] Lin JZ, Long JY, Wang AQ, et a. Precision medicine: In need of guidance and surveillance[J]. World J Gastroenterol, 2017, 23(28):19-24. http://www.wjgnet.com/1007-9327/full/v23/i28/5045.htm
    [25] 王玮, 孙哲, 邓靖宇, 等.基于多中心大样本数据库的胃癌外科治疗相关数据的整合与分析[J].中华胃肠外科杂志, 2016, 19(2):179-185. doi: 10.3760/cma.j.issn.1671-0274.2016.02.014
    [26] 中国胃肠肿瘤外科联盟.中国胃肠肿瘤外科联盟数据报告(2014-2016) [J].中国实用外科杂志, 2018, 38(1):90-93. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201801028.htm
    [27] Kline R. Cybernetics, automata studies, and the dartmouth conference on artificial intelligence[M]. IEEE Educational Activities Department, 2011.
    [28] Patel VL, Shortliffe EH, Stefanelli M, et al. Position paper: The coming of age of artificial intelligence in medicine[J]. Artificial Intelli Med, 2009, 46(1):5-17. http://dare.uva.nl/record/1/321559
    [29] Kanesaka T, Lee TC, Uedo N, et al. Computer- aided diagnosis for identifying and delineating early gastric cancers in magnifying narrowband images[J]. Gastrointest Endosc, 2017, 87(5):1339-1344. http://www.sciencedirect.com/science/article/pii/S001651071732535X
    [30] Park S, Parwani A, Aller R, et al. The history of pathology informatics: A global perspective[J]. J Pathol Inform, 2013, 4(1):7. doi: 10.4103/2153-3539.112689
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  100
  • HTML全文浏览量:  17
  • PDF下载量:  13
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-10-29
  • 修回日期:  2018-12-24
  • 刊出日期:  2019-01-15

目录

    /

    返回文章
    返回

    版权所有 © 2013《中国肿瘤临床》编辑部津ICP备09011441号-3

    地址：天津市河西区体院北环湖西路肿瘤医院内 300060电话/传真：(022)23527053Email：cjco@cjco.cn

    本系统由北京仁和汇智信息技术有限公司开发    百度统计